ILUMYA SUPPORT® FOR YOUR PATIENTS AND YOUR PRACTICE

SUPPORT FOR YOUR ILUMYA® PATIENTS AND YOUR PRACTICE

ILUMYA_Support_Logo_Tag_KO

ILUMYA SUPPORT® offers comprehensive programs and services to help patients start and stay on therapy.

You can get patients started by enrolling them in ILUMYA SUPPORT® or sending their prescription directly to any specialty pharmacy provider (SPP).

ILUMYA SUPPORT® can provide:

  • Dedicated Field Reimbursement Managers to support your practice
  • Regionally based ILUMYA SUPPORT® Case Managers to support your patients and your practice
  • Details about plan-specific prior authorization (PA) requirements and assistance with the appeals process for PAs
  • Comprehensive patient services, including financial assistance options
  • Ongoing support for your practice through status updates and next steps

ILUMYA SUPPORT® makes it easy to use your preferred SPP

  • Our open access network does not restrict your choice of SPP
    • Please note ILUMYA® may be covered under a patient’s medical or pharmacy benefit. Submit information on both at the time of initiating a BI
  • Indicate your preferred SPP when completing the ILUMYA SUPPORT® Patient Services Enrollment Form
    • If not specified on the enrollment form, SPP referrals will be made according to the payer’s mandate or sent to an SPP in our network

*HCPs can also enroll patients through the ILUMYA® Provider Portal at www.ILUMYASUPPORT.com.

Early Access Program

Commercial patients who receive a PA may be eligible to receive free medication

After the Provider submits a completed ILUMYA SUPPORT® Patient Services Enrollment Form, ILUMYA SUPPORT® processes the enrollment form, sends the provider a benefits summary, and automatically adds the commercially insured patient to the Early Access Program without the need for an initial prior authorization (PA)

Patient continuation in the Early Access Program is contingent on provider submission of a medical and/or pharmacy PA before a patient’s third dose of ILUMYA®. Once the medical and/or pharmacy PA is received, patients can receive ILUMYA® (tildrakizumab-asmn) free for up to 2 years or until they obtain insurance coverage approval, whichever occurs earlier

Co-pay Program

Patients pay no more than $5 per dose of ILUMYA® (tildrakizumab-asmn)

Available to eligible patients with commercial insurance

Patient Assistance Program

Patients who are underinsured or uninsured may be eligible to receive free medication§

Foundation support

ILUMYA SUPPORT® can refer eligible patients to independent third-party foundations to receive other financial assistance

Financial disclosures may be required

The foundation creates, establishes, and administers the funds at its own discretion.

ILUMYA SUPPORT Lighting the Way® Patient Program

Dedicated patient program helps patients along their ILUMYA® journey
Download Patient Services
Enrollment FormDownload Arrow
Download Arrow

NICA_Chair_Icon CopyCreated with Sketch.

National Infusion Center Association

Sun Pharma has partnered with the National Infusion Center Association (NICA) to help your qualified ILUMYA® patients and your practice find alternative sites of care in your area

Subject to Terms and Conditions. Must be enrolled in ILUMYA SUPPORT® to qualify.

$16,000 maximum program benefit per calendar year. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE.

§Income documentation is required. Subject to Terms and Conditions. Available to US, Guam, Virgin Islands, or Puerto Rico residents only.

Use the permanent J-code for ILUMYA® issued by CMS for administrative and billing purposes.

For specific coding policies and questions, please contact your local payer or Dedicated Field Reimbursement Manager.

ILUMYA SUPPORT® is available every step of the way to help your patients and your practice. For assistance, please call 855‑4ILUMYA (855‑445‑8692)855-4ILUMYA (855-445-8692), Monday through Friday, 8 am to 8 pm ET.

CMS=Centers for Medicare & Medicaid Services; HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code.

ILUMYA® can now be purchased from any of the below preferred specialty distributors:

Enroll Online:

Call to Enroll:

To purchase ILUMYA® via any of the 5 preferred specialty distributors:

To learn more, contact your Field Reimbursement Manager

For more details on reimbursement, 
click here.

The ILUMYA® Provider Portal offers a fast and simple way to help monitor the status of your patients’ ILUMYA® prescriptions in real time. The design of the ILUMYA® Provider Portal was guided by the needs of busy office staff, with the goal of improving patient access to ILUMYA®.

Overview of the ILUMYA® Provider Portal capabilities

Dosing Body Icon

Real-time monitoring of patient status

Electronic_Ptnt_ICON_2

Electronic patient enrollment for ILUMYA SUPPORT® services

Case status

Co-pay status

Bar_Graph_ICON

Monitor patient co-pay enrollment/activity for eligible patients

Case update notifications

Phone IconIf you have questions, please contact ILUMYA SUPPORT® at 855-4ILUMYA (855-445-8692), Monday through Friday, 8 am to 8 pm ET.

Register or log in to the ILUMYA® Provider Portal to monitor the status of your patients’ ILUMYA® prescriptions in real time

Visit
ILUMYASUPPORT.com

Short on time? Learn about the key attributes of ILUMYA® (tildrakizumab-asmn) in under 4 minutes. This dynamic video showcases the most important information you need to know about the long-term efficacy, durable safety, quarterly dosing, and mechanism of action of ILUMYA®.

Resources for your patients

Help your patients take advantage of all that ILUMYA® has to offer by prompting them to visit ILUMYA.com.

This patient-focused content can offer valuable insight and materials, including:

  • What to expect when taking ILUMYA®
  • The key advantages and details about ILUMYA®
  • Help joining our patient support program, ILUMYA SUPPORT Lighting the Way®
  • Access to resources for initial and continued success during their treatment with ILUMYA®

INDICATION AND IMPORTANT SAFETY INFORMATION

ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CONTRAINDICATIONS

ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity

Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.

Infections

ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.

Pretreatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.

Immunizations

Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.

Adverse Reactions

The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

Please see full Prescribing Information.